NCT00665093已完成不适用
A Prospective, Multicentre, Open Label, Non-controlled, Observational, 24-week Study in Patients Using NovoMix® 30 (Biphasic Insulin Aspart 30) or Levemir® (Insulin Detemir) for Treatment of Type 1 or Type 2 Diabetes Mellitus in Macedonia
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,569
- 试验地点
- 1
- 主要终点
- HbA1c
研究概览
简要总结
This trial is conducted in Europe. The aim of this observational study is to evaluate the glycaemic control in patients with type 1 or 2 diabetes using NovoMix® 30 or Levemir® under normal clinical practice conditions.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Levemir® above 6 yrs
- •NovoMix® 30 above 18 yrs
- •Patients with Type 1 or Type 2 diabetes, including newly diagnosed
排除标准
- •Current treatment with NovoMix® 30 or Levemir®
研究组 & 干预措施
A
干预措施: biphasic insulin aspart 30 (Drug)
B
干预措施: insulin detemir (Drug)
结局指标
主要结局
HbA1c
时间窗: at 24 weeks
次要结局
- FPG, PG profile, weight, % of subjects on target(at 24 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Observational Study of Type 1 and Type 2 Diabetes Patients Having Switched From Human Premixes to NovoMix®30DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2NCT00675493Novo Nordisk A/S942
已完成
不适用
Observational Study of Type 1 Diabetics Switching From Human Insulins to Modern Insulin AnaloguesDiabetesDiabetes Mellitus, Type 1NCT00873639Novo Nordisk A/S417
已完成
不适用
Observational Study on Effectiveness and Safety of Liraglutide in Subjects With Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT01288326Novo Nordisk A/S254
已完成
不适用
Observational Study of NovoMix® 50 for Treatment of Type 2 Diabetics for 12 MonthsDiabetesDiabetes Mellitus, Type 2NCT00755833Novo Nordisk A/S270
已完成
3 期
Comparison of Biphasic Human Insulin 30 With Biphasic Insulin Aspart in Subjects With DiabetesDiabetes Mellitus, Type 1DiabetesDiabetes Mellitus, Type 2NCT01520818Novo Nordisk A/S666